Randomized Phase 2 Trial of Intracoronary Nitrite During Acute Myocardial Infarction. Issue 3 (30th January 2015)

• Record Type: Journal Article
• Authors: Jones, Daniel A.; Pellaton, Cyril; Velmurugan, Shanti; Rathod, Krishnaraj Sinha; Andiapen, Mervyn; Antoniou, Sotiris; van Eijl, Sven; Webb, Andrew J.; Westwood, Mark A.; Parmar, Mahesh K.; Mathur, Anthony; Ahluwalia, Amrita
• Is Part Of: Circulation research. Volume 116:Issue 3(2015)
• Publication Date: 2015-01-30
• Subjects: Cardiovascular system -- Periodicals; Blood -- Circulation -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; Sang -- Circulation -- Périodiques; Appareil cardiovasculaire -- Périodiques; 612.1
• DOI: 10.1161/CIRCRESAHA.116.305082
• Languages: English
• ISSNs: 0009-7330

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title> <underline>Rationale:</underline> </title> <p>Preclinical evidence demonstrates that inorganic nitrite, after its in situ conversion to nitric oxide, attenuates consequent myocardial reperfusion injury.</p> </sec> <sec> <title> <underline>Objective:</underline> </title> <p>We investigated whether intracoronary injection of nitrite during primary percutaneous coronary intervention might improve infarct size in ST-elevated myocardial infarction.</p> </sec> <sec> <title> <underline>Methods and Results:</underline> </title> <p>Patients undergoing primary percutaneous coronary intervention (n=80) were randomized to receive intracoronary (10 mL) sodium nitrite (1.8 μmol) or NaCl (placebo) before balloon inflation. The primary end point was infarct size assessed by measuring creatine kinase release. Secondary outcomes included infarct size assessed by troponin T release and by cardiac MRI on day 2. Baseline characteristics were similar between the groups. No evidence of differences in creatine kinase release (<italic>P</italic>=0.92), troponin T (<italic>P</italic>=0.85), or cardiac MRI–assessed infarct size (<italic>P</italic>=0.254) were evident. In contrast, there was a reduction in myocardial salvage index (<italic>P</italic>=0.05) and major adverse cardiac event at 1 year (2.6% versus 15.8%; <italic>P</italic>=0.04) in the nitrite group. In a 66-patient subgroup with thrombolysis in myocardial infarction ⩽1 flow, there was reduced serum creatine kinase (<italic>P</italic>=0.030) and a 19% reduction in cardiac MRI–determined infarct size (<italic>P</italic>=0.034) with nitrite. No adverse effects of nitrite were detected.</p> </sec> <sec> <title> <underline>Conclusions:</underline> </title> <p>In this phase II study, intracoronary nitrite infusion did not alter infarct size, although a trend to improved myocardial salvage index and a significant reduction in major adverse cardiac event was evident. In a subgroup of patients with thrombolysis in myocardial infarction flow ⩽1, nitrite reduced infarct size and major adverse cardiac event and improved myocardial salvage index, indicating that a phase III clinical trial assessing intracoronary nitrite administration as an adjunct to percutaneous coronary intervention in ST-elevated myocardial infarction patients is warranted.</p> </sec> <sec> <title> <underline>Clinical Trial Registration:</underline> </title> <p>URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.clinicaltrials.gov</ext-link>. Unique identifier: NCT01584453.</p> </sec> </abstract>